Skip to main content

Table 1 Basic molecular and clinicopathological characteristics of the study series

From: Identification of subgroup-specific miRNA patterns by epigenetic profiling of sporadic and Lynch syndrome-associated colorectal and endometrial carcinoma

  Finnish CRC Australian CRC Finnish EC
  Sporadic MSS Sporadic MSI Lynch Sporadic MSS Sporadic MSI Lynch
Total number of tumors 47 40 28 52 38 36
Gender       
Female 27 27 12 25 20 36
Male 20 13 16 27 18 -
Mean age of diagnosis (years) 69.9 72.8 43.6 67.6 67.1 50.2
Germline mutation present in MMR genes (total) N/A N/A 28 N/A N/A 36
MLH1    28    30
MSH2    0    3
MSH6    0    3
MMR statusa       
Deficient 0 40 28 0 38 36
Proficient 47 0 0 52 0 0
Tumor grade       
1 13/21 5/14 5/16 1/52 0/36 14/29
2 5/21 6/14 6/16 46/52 24/36 9/29
3 3/21 3/14 5/16 5/52 12/36 6/29
Tumor stage (Dukes/WHO/FIGO)b       
A/I/I 7/46 2/37 5/19 8/52 3/38 12/22
B/II/II 16/46 24/37 10/19 24/52 20/38 7/22
C/III/III 16/46 8/37 4/19 17/52 13/38 1/22
D/IV/IV 7/46 3/37 0/19 3/52 2/38 3/22
Location of CRCc       
Proximal 20/44 34/39 22/27 20/52 27/38 -
Distal 24/44 5/39 5/27 32/52 11/38 -
  1. N/A, not applicable. aBased on microsatellite instability and immunohistochemical staining; baccording to the Dukes (A-D), World Health Organization (WHO) (I-IV), and International Federation of Gynecology and Obstetrics (FIGO) (I-IV) staging for CRC and EC, respectively. The denominator indicates the number of tumors for which data were available. cPrior to the splenic flexure for ‘proximal’ and distal to the splenic flexure for ‘distal’ (the denominator indicates the number of tumors with data available).